Impact of COVID-19 lockdown on the incidence and mortality of acute exacerbations of chronic obstructive pulmonary disease: national interrupted time series analyses for Scotland and Wales.
Acute exacerbation of chronic obstructive pulmonary disease
COVID-19 lockdown
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
17 05 2021
17 05 2021
Historique:
received:
12
01
2021
accepted:
30
04
2021
entrez:
17
5
2021
pubmed:
18
5
2021
medline:
4
6
2021
Statut:
epublish
Résumé
The COVID-19 pandemic and ensuing national lockdowns have dramatically changed the healthcare landscape. The pandemic's impact on people with chronic obstructive pulmonary disease (COPD) remains poorly understood. We hypothesised that the UK-wide lockdown restrictions were associated with reductions in severe COPD exacerbations. We provide the first national level analyses of the impact of the COVID-19 pandemic and first lockdown on severe COPD exacerbations resulting in emergency hospital admissions and/or leading to death as well as those recorded in primary care or emergency departments. Using data from Public Health Scotland and the Secure Anonymised Information Linkage Databank in Wales, we accessed weekly counts of emergency hospital admissions and deaths due to COPD over the first 30 weeks of 2020 and compared these to the national averages over the preceding 5 years. For both Scotland and Wales, we undertook interrupted time-series analyses to model the impact of instigating lockdown on these outcomes. Using fixed-effect meta-analysis, we derived pooled estimates of the overall changes in trends across the two nations. Lockdown was associated with 48% pooled reduction in emergency admissions for COPD in both countries (incidence rate ratio, IRR 0.52, 95% CI 0.46 to 0.58), relative to the 5-year averages. There was no statistically significant change in deaths due to COPD (pooled IRR 1.08, 95% CI 0.87 to 1.33). In Wales, lockdown was associated with 39% reduction in primary care consultations for acute exacerbation of COPD (IRR 0.61, 95% CI 0.52 to 0.71) and 46% reduction in COPD-related emergency department attendances (IRR 0.54, 95% CI 0.36 to 0.81). The UK-wide lockdown was associated with the most substantial reductions in COPD exacerbations ever seen across Scotland and Wales, with no corresponding increase in COPD deaths. This may have resulted from reduced transmission of respiratory infections, reduced exposure to outdoor air pollution and/or improved COPD self-management.
Sections du résumé
BACKGROUND
The COVID-19 pandemic and ensuing national lockdowns have dramatically changed the healthcare landscape. The pandemic's impact on people with chronic obstructive pulmonary disease (COPD) remains poorly understood. We hypothesised that the UK-wide lockdown restrictions were associated with reductions in severe COPD exacerbations. We provide the first national level analyses of the impact of the COVID-19 pandemic and first lockdown on severe COPD exacerbations resulting in emergency hospital admissions and/or leading to death as well as those recorded in primary care or emergency departments.
METHODS
Using data from Public Health Scotland and the Secure Anonymised Information Linkage Databank in Wales, we accessed weekly counts of emergency hospital admissions and deaths due to COPD over the first 30 weeks of 2020 and compared these to the national averages over the preceding 5 years. For both Scotland and Wales, we undertook interrupted time-series analyses to model the impact of instigating lockdown on these outcomes. Using fixed-effect meta-analysis, we derived pooled estimates of the overall changes in trends across the two nations.
RESULTS
Lockdown was associated with 48% pooled reduction in emergency admissions for COPD in both countries (incidence rate ratio, IRR 0.52, 95% CI 0.46 to 0.58), relative to the 5-year averages. There was no statistically significant change in deaths due to COPD (pooled IRR 1.08, 95% CI 0.87 to 1.33). In Wales, lockdown was associated with 39% reduction in primary care consultations for acute exacerbation of COPD (IRR 0.61, 95% CI 0.52 to 0.71) and 46% reduction in COPD-related emergency department attendances (IRR 0.54, 95% CI 0.36 to 0.81).
CONCLUSIONS
The UK-wide lockdown was associated with the most substantial reductions in COPD exacerbations ever seen across Scotland and Wales, with no corresponding increase in COPD deaths. This may have resulted from reduced transmission of respiratory infections, reduced exposure to outdoor air pollution and/or improved COPD self-management.
Identifiants
pubmed: 33993870
doi: 10.1186/s12916-021-02000-w
pii: 10.1186/s12916-021-02000-w
pmc: PMC8126470
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
124Subventions
Organisme : Medical Research Council
ID : MC_PC_19004
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R008345/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/V028367/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_19075
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_13043
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K006525/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_20058
Pays : United Kingdom
Investigateurs
Colin R Simpson
(CR)
Jim McMenamin
(J)
Lewis D Ritchie
(LD)
Mark Woolhouse
(M)
Helen R Stagg
(HR)
Diogo Marques
(D)
Josie Murray
(J)
Sarah Stock
(S)
Rachael Wood
(R)
Colin McCowan
(C)
Utkarsh Agrawal
(U)
Annemarie B Docherty
(AB)
Rachel H Mulholland
(RH)
Emily Moore
(E)
James Marple
(J)
Vicky Hammersley
(V)
Références
Thorax. 2021 Sep;76(9):867-873
pubmed: 33782079
Thorax. 2021 Sep;76(9):939-941
pubmed: 33782081
PLoS Med. 2020 Feb 6;17(2):e1003041
pubmed: 32027644
BMC Med Inform Decis Mak. 2009 Jan 16;9:3
pubmed: 19149883
Heart. 2021 Jan;107(2):113-119
pubmed: 32988988
Int J Chron Obstruct Pulmon Dis. 2020 Sep 23;15:2237-2248
pubmed: 33061341
Respir Med. 2022 Jan;191:106120
pubmed: 32839072
Lancet Oncol. 2020 Aug;21(8):1023-1034
pubmed: 32702310
BMJ Open. 2020 Sep 9;10(9):e040951
pubmed: 32912958
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Respir Med. 2020 Sep;171:106085
pubmed: 32917356
Int J Chron Obstruct Pulmon Dis. 2020 Oct 23;15:2621-2627
pubmed: 33122900
BMJ. 2020 Oct 20;371:m3731
pubmed: 33082154
Int J Chron Obstruct Pulmon Dis. 2017 Jan 17;12:313-322
pubmed: 28176888
JAMA. 2020 Jul 7;324(1):96-99
pubmed: 32501493
Chest. 2021 Jul;160(1):135-138
pubmed: 33444614
Chest. 2002 May;121(5 Suppl):136S-141S
pubmed: 12010842
Scand J Public Health. 2021 Nov;49(7):681-688
pubmed: 33764202
BMJ. 2020 Jul 15;370:m2806
pubmed: 32669279
Int J Chron Obstruct Pulmon Dis. 2020 Oct 14;15:2487-2494
pubmed: 33116465
BMC Emerg Med. 2021 Apr 6;21(1):42
pubmed: 33823795
J Allergy Clin Immunol Pract. 2020 Sep;8(8):2489-2491
pubmed: 32497662
Arch Dis Child. 2020 Aug;105(8):809-810
pubmed: 32444452
Eur J Emerg Med. 2020 Aug;27(4):305-306
pubmed: 32345851
PLoS Med. 2015 Oct 06;12(10):e1001885
pubmed: 26440803
J R Soc Med. 2020 Nov;113(11):444-453
pubmed: 33012218
ERJ Open Res. 2021 Jan 18;7(1):
pubmed: 33527075
COPD. 2021 Apr;18(2):226-230
pubmed: 33764237
PLoS One. 2016 Mar 09;11(3):e0151357
pubmed: 26959820
ERJ Open Res. 2021 Feb 08;7(1):
pubmed: 33575313
J Public Health (Oxf). 2021 Sep 22;43(3):517-520
pubmed: 33539527
Dtsch Arztebl Int. 2020 Aug 17;117(33-34):545-552
pubmed: 32865489
Thorax. 2021 May;76(5):512-513
pubmed: 33273024
Health Aff (Millwood). 2020 Nov;39(11):2010-2017
pubmed: 32970495
Air Qual Atmos Health. 2021;14(3):325-332
pubmed: 32952739
Thorax. 2020 Jun;75(6):446-447
pubmed: 32398319
Respiration. 2021;100(7):588-593
pubmed: 33827103
Int J Popul Data Sci. 2019 Nov 20;4(2):1134
pubmed: 34095541
BMJ. 2020 May 22;369:m1985
pubmed: 32444460